European Collaborative Project

HORIZON 21

Down syndrome and Alzheimer’s disease

Horizon 21 Consortium

Stop Alzheimer's before it starts

A european consortium with research teams from 10 different european sites, to develop clinical trials in order to prevent or delay Alzheimer’s disease in the population with Down syndrome.

KEY NUMBERS

0
CURRENT PROJECTS
0
COUNTRIES
0
RESEARCHERS INVOLVED
0
INCLUSIONS

WHO WE ARE?

The Horizon 21 Consortium was born from a collaboration between clinicians from various european centers offering a consultation dedicated to adults and seniors with Down syndrome.

This program aims at identifying the factors that influence the development of Alzheimer’s disease in persons with Down syndrome. The consortium wants also to develop cognitive assesment tools and biomarkers which could be relevant for clinical trials. Of course, the main objective is to prevent and/or delay the onset of Alzheimer’s disease in this specific population.

meeting-londres-novembre21-_2_

Our Projects

Genetic markers

Large-scale genotyping of persons with Down syndrome in order to identify risk or protective factors of Alzheimer's disease.

Cognitive evaluation tools

Harmonisation of cognitive evaluation tools

Biological markers

e.g neurofilaments light analysis in plasma.

Sleep evaluation

Impact of Alzheimer’s disease on sleep of adults with Down syndrome.

The consoritum had a zoom meeting on the 05.06.2021 with more than 40 participants for a full day of training…

The Horizon 21 consortium participated to the T21RS virtual conference on the 06.10.2021 (Symposium 5 : Alzheimer's disease and Down…

Consortium’s members are going to meet in person for the first time since the beginning of the pandemic. The main…

Welcome on our new website !

We are very pleased to welcome you on our new website. You will find on this website all the informations relative to the Horizon 21 consortium.

Discover our Research Centers

8 Countries, 10 CENTERS
  • European Consortium